Andrew Hurd

Mr. Hurd is one of the most accomplished entrepreneurial CEOs in the healthcare information technology industry. Presently he serves as CEO of MedeAnalytics which he joined as Chairman and Chief Executive Officer in May 2013. He has more than 25 years of experience in digital health, including product and market innovation as well as strategic partnerships.

Prior to MedeAnalytics, Mr. Hurd was CEO of Epocrates (Nasdaq: EPOC), which was acquired by athenahealth (Nasdaq: ATHN). Prior to Epocrates, he served as chairman and CEO of Carefx, which was acquired by Harris Corporation (NYSE: HRS) in 2011. During his six-year tenure at Carefx, the company achieved strong growth in revenue, income and shareholder value. Before Carefx, Hurd held senior management positions at WebMD (Nasdaq: WBMD) and QuadraMed Corporation.

Mr. Hurd holds a bachelor’s degree in business administration from Northern Arizona University, and is a member of the board of directors of Ability Networks.